Cargando…

Evaluation of changes in ferritin levels during sucroferric oxyhydroxide treatment

BACKGROUND: A sub-analysis of a Phase III study was conducted to identify factors that might predict increased ferritin levels during long-term sucroferric oxyhydroxide (SO) treatment in hemodialysis patients. METHODS: The open-label, multicenter, Phase III study assessed the efficacy and safety of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koiwa, Fumihiko, Yokoyama, Keitaro, Fukagawa, Masafumi, Akizawa, Tadao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Anemia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452212/ https://www.ncbi.nlm.nih.gov/pubmed/30976411 http://dx.doi.org/10.1093/ckj/sfy077

Ejemplares similares

Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients
por: Koiwa, Fumihiko, et al.
Publicado: (2017)

Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open‐label, multicentre, 12‐week phase III study
por: Koiwa, Fumihiko, et al.
Publicado: (2017)

Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric  Oxyhydroxide
por: Cozzolino, Mario, et al.
Publicado: (2014)

The anemias; with special reference to pernicious anemia and the use of liver extracts in the treatment of anemias. Supplement: Blood morphology in diagnosis.
Publicado: (1950)

Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis
por: Meadowcroft, Amy M, et al.
Publicado: (2018)

Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease
por: Holdstock, Louis, et al.
Publicado: (2018)

Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure
por: Caltabiano, Stephen, et al.
Publicado: (2019)

First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties
por: Kazama, Junichiro James, et al.
Publicado: (2022)

Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide
por: Covic, Adrian C., et al.
Publicado: (2017)

Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence
por: Coyne, Daniel W., et al.
Publicado: (2022)

Impact of sucroferric oxyhydroxide on the oral and intestinal microbiome in hemodialysis patients
por: Abdelbary, Mohamed M. H., et al.
Publicado: (2022)

Bicarbonate levels in hemodialysis patients switching from lanthanum carbonate to sucroferric oxyhydroxide
por: Stavroulopoulos, Aristeidis, et al.
Publicado: (2018)

Sucroferric Oxyhydroxide in Maintenance Hemodialysis: A Retrospective, Comparative Cohort Study
por: Coyne, Daniel W., et al.
Publicado: (2020)

Real-world management of hyperphosphataemia with sucroferric oxyhydroxide: the VELREAL multicentre study
por: Navarro-González, Juan F, et al.
Publicado: (2021)

Safety and efficacy of sucroferric oxyhydroxide in pediatric patients with chronic kidney disease
por: Greenbaum, Larry A., et al.
Publicado: (2020)

First-in-Human Phase I Study of the Novel Injectable Calcimimetic Agent Upacicalcet in Healthy Adult Japanese Participants
por: Koiwa, Fumihiko, et al.
Publicado: (2022)

Phosphate binding by sucroferric oxyhydroxide ameliorates renal injury in the remnant kidney model
por: Nemoto, Yoshikazu, et al.
Publicado: (2019)

Renoprotective effects of sucroferric oxyhydroxide in a rat model of chronic renal failure
por: Neven, Ellen, et al.
Publicado: (2020)

Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients
por: Floege, Jürgen, et al.
Publicado: (2015)

Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients
por: Koiwa, Fumihiko, et al.
Publicado: (2021)

Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia
por: Koiwa, Fumihiko, et al.
Publicado: (2023)

Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis
por: Yokoyama, Keitaro, et al.
Publicado: (2019)

One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis
por: Kendrick, Jessica, et al.
Publicado: (2019)

Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients: a prospective observational study
por: Vervloet, Marc G, et al.
Publicado: (2021)

Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients
por: Shima, Hisato, et al.
Publicado: (2018)

Drug–drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects
por: Chong, Edward, et al.
Publicado: (2014)

Effectiveness of sucroferric oxyhydroxide in patients on on-line hemodiafiltration in real-world clinical practice: A retrospective study
por: Ferreira, Aníbal, et al.
Publicado: (2019)

Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data
por: Coyne, Daniel W., et al.
Publicado: (2017)

Gut microbiome in hemodialysis patients treated with calcium acetate or treated with sucroferric oxyhydroxide: a pilot study
por: Merino-Ribas, Ana, et al.
Publicado: (2021)

Effect of the phosphate binder sucroferric oxyhydroxide in dialysis patients on endogenous calciprotein particles, inflammation, and vascular cells
por: Thiem, Ursula, et al.
Publicado: (2022)

New clinical guidelines for selective direct injection therapy of the parathyroid glands in chronic dialysis patients
por: Onoda, Noritaka, et al.
Publicado: (2008)

Percutaneous ethanol injection therapy for advanced renal hyperparathyroidism in Japan: 2004 survey by the Japanese Society for Parathyroid Intervention
por: Kakuta, Takatoshi, et al.
Publicado: (2008)

Iron kinetics following treatment with sucroferric oxyhydroxide or ferric citrate in healthy rats and models of anaemia, iron overload or inflammation
por: Floege, Jürgen, et al.
Publicado: (2020)

Phosphate binder pill burden, adherence, and serum phosphorus control among hemodialysis patients converting to sucroferric oxyhydroxide
por: Gray, Kathryn, et al.
Publicado: (2019)

Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease–mineral bone disorder parameters in dialysis patients
por: Ketteler, Markus, et al.
Publicado: (2019)

The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis
por: Ramos, Rosa, et al.
Publicado: (2020)

A 6-Month clinical practice pilot study of sucroferric oxyhydroxide on nutritional status in patients on peritoneal dialysis
por: Perez, Luis, et al.
Publicado: (2022)

Preventing and controlling iron deficiency anaemia through primary health care: a guide for health administrators and programme managers
por: DeMaeyer, E. M.
Publicado: (1989)

Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patients
por: Minakuchi, Hitoshi, et al.
Publicado: (2020)

A comparison between the combined effect of calcium carbonate with sucroferric oxyhydroxide and other phosphate binders: an in vitro and in vivo experimental study
por: Yaguchi, Atsushi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_k85bsi9p3386qifqmits9ft3lt